Veristat Featured Articles
-
Marketing Application Publishing Best Practices
12/7/2022
Explore how effectively managing the publishing of documents required for a marketing application submission can help accelerate the time it takes to bring your product to market.
-
Autologous And Allogeneic Cell Therapies: Benefits, Challenges, And Future Prospects
10/24/2022
In this blog, explore both autologous and allogeneic approaches, the solutions needed to optimize the development processes for commercial viability, and the future landscape of cell therapies in the rare disease space.
-
Key Considerations For Small & Mid-Size Sponsors Conducting Decentralized Or Hybrid Trials
9/12/2022
Read this webinar presentation as panelists share lessons learned and recommendations for designing protocols that enable flexibility in your virtual trials’ conduct.
-
A Paradigm Shift In Monitoring Clinical Trials
5/31/2022
Today, the shift and the changes in how we work has affected how clinical trial monitoring is conducted and performed. Explore how re-tooling the clinical monitoring in clinical trials has become imperative.
-
Planning The Way Forward In Neurodegenerative Disease Studies
7/14/2021
The recent FDA guidance entitled "Human Gene Therapy for Neurodegenerative Diseases" (ND) provides recommendations for Sponsors who are developing human gene therapy (GT) products for neurodegenerative diseases, which affect adult and pediatric patients. It focuses on considerations for product development, preclinical testing, clinical trial design and marketing approval pathways. This article outlines several areas to consider when preparing for regulatory agency interactions.